- Home
- NUTR vs XFOR Comparison
NUTR vs XFOR Comparison
Compare NUTR & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUTR
- XFOR
- Stock Information
- Founded
- NUTR 2013
- XFOR 2014
- Country
- NUTR Indonesia
- XFOR United States
- Employees
- NUTR N/A
- XFOR N/A
- Industry
- NUTR
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUTR
- XFOR Health Care
- Exchange
- NUTR Nasdaq
- XFOR Nasdaq
- Market Cap
- NUTR 87.9M
- XFOR 84.3M
- IPO Year
- NUTR 2025
- XFOR N/A
- Fundamental
- Price
- NUTR $5.02
- XFOR $3.38
- Analyst Decision
- NUTR
- XFOR Strong Buy
- Analyst Count
- NUTR 0
- XFOR 3
- Target Price
- NUTR N/A
- XFOR $34.17
- AVG Volume (30 Days)
- NUTR 1.3M
- XFOR 5.8M
- Earning Date
- NUTR 11-02-2025
- XFOR 08-08-2025
- Dividend Yield
- NUTR N/A
- XFOR N/A
- EPS Growth
- NUTR N/A
- XFOR N/A
- EPS
- NUTR 0.00
- XFOR N/A
- Revenue
- NUTR $1,743,679.00
- XFOR $32,774,000.00
- Revenue This Year
- NUTR N/A
- XFOR $1,313.84
- Revenue Next Year
- NUTR N/A
- XFOR N/A
- P/E Ratio
- NUTR $2,018.91
- XFOR N/A
- Revenue Growth
- NUTR N/A
- XFOR 5721.31
- 52 Week Low
- NUTR $3.40
- XFOR $1.35
- 52 Week High
- NUTR $5.17
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- NUTR N/A
- XFOR 53.83
- Support Level
- NUTR N/A
- XFOR $3.05
- Resistance Level
- NUTR N/A
- XFOR $3.79
- Average True Range (ATR)
- NUTR 0.00
- XFOR 0.53
- MACD
- NUTR 0.00
- XFOR -0.09
- Stochastic Oscillator
- NUTR 0.00
- XFOR 30.66
About NUTR Nusatrip Incorporated Common Stock
NusaTrip Inc operates as an Online Travel Agent offering Hotel & Flight Tickets, Domestic and International. The Company currently operates in a single reportable operating segment with five different services: Ticketing, Online advertisement, Hotel reservation, Hotel technology platform software, and Ancillary. The group earns revenue through commissions, service fees, and advertising partnerships.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.